Bayer, CRISPR Tap Sanofi Exec, Burns, to Run Gene Editing Venture

Xconomy Boston — 

Bayer and CRISPR Therapeutics (NASDAQ: CRSP) have named James Burns the president and CEO of Cambridge, MA-based Casebia Therapeutics, a joint venture the two companies created to develop gene editing drugs for blood disorders, blindness, and heart disease. Burns has been at Sanofi/Genzyme for three decades, and most recently ran the company’s North American R&D hub. Bayer executive Axel Bouchon had been serving as Casebia’s interim CEO.